

Preclinical oncology biotech Immunome files for a \$30 million IPO

September 9, 2020



Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, filed on Wednesday with the SEC to raise up to \$30 million in an initial public offering.

The company is developing first-in-class antibody therapeutics based on its proprietary human memory B cell platform. The company's lead discovery program, IMM-ONC-01, is focused on interleukin-38, a small protein which appears to function as a novel immune checkpoint inhibitor. Immunome expects to file an IND for IMM-ONC-01 in the 2H21 upon successful completion of its preclinical evaluation.

The Exton, PA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol [IMNM](#). Immunome filed confidentially on August 12, 2020. Ladenburg Thalmann and Chardan Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

Relevant Profile: [IMNM](#)

Source: Renaissance Capital